Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Cognition Therapeutics Inc
(NQ:
CGTX
)
0.4721
-0.0589 (-11.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
492,579
Open
0.5200
Bid (Size)
0.4750 (30)
Ask (Size)
0.4989 (3)
Prev. Close
0.5310
Today's Range
0.4700 - 0.5200
52wk Range
0.3400 - 2.950
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
Today 16:15 EDT
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
October 29, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
-75.66%
-75.66%
1 Month
+0.75%
+0.75%
3 Month
-52.79%
-52.79%
6 Month
-75.79%
-75.79%
1 Year
-57.85%
-57.85%
More News
Read More
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
October 23, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
October 22, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
October 02, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
October 01, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
September 30, 2024
Via
Benzinga
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
September 03, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
August 22, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q2 2024
August 08, 2024
Via
InvestorPlace
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
August 08, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
August 05, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
July 30, 2024
Via
InvestorPlace
Dow Edges Lower; Ventyx Biosciences Shares Plummet
July 29, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 29, 2024
Via
Benzinga
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump
July 29, 2024
Via
Benzinga
Exposures
Fossil Fuels
Tivic Health Systems (TIVC) Stock Pops Another 39%
July 29, 2024
Via
InvestorPlace
Cognition Therapeutics Stock Tumbles On Mixed Data From Mid-Stage Alzheimer's Study
July 29, 2024
Via
Benzinga
Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?
July 29, 2024
Via
InvestorPlace
Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?
July 29, 2024
Via
InvestorPlace
Nasdaq Gains 1%; McDonald's Posts Downbeat Results
July 29, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
July 29, 2024
Via
InvestorPlace
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
July 29, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
July 29, 2024
Via
Benzinga
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
July 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.